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THE IMMUNOHEMATOLOGY 
CONSULTATION REPORT 
WHAT, WHEN, HOW MUCH? 
Kathryn M. Beattie 
Introduction 
There is no doubt about the mandate to maintain 
blood bank records and reports. The Code of Federal 
Regulations (CFR 606.160) states: 
Records shall be maintained that include, but 
(b) (4) Compatibility test records: 
are not limited to the following: 
(i) Results of all compatibility tests, 
including crossmatching, testing of 
patient samples, antibody screening 
and identification. 
(ii) Results of confirmatory testing. 
(6)  Transfusion reaction reports and com- 
plaints, including records of investiga- 
tions and follow-up. 
The American Red Cross (ARC) Blood Service Direc- 
tive 6.5 explains in detail how ARC reference labora- 
tories must comply with the Federal Regulations for 
records. It states: 
Each patient specimen studied must have the 
A. Antibody identification including special 
following records: 
cell typing and a report to the submitting 
hospital. 
B. Units screened and found compatible. 
C. All special typings or procedures 
performed. 
It also says these records must be kept indefinitely. 
Immunohematology Reference Laboratory 
Reports 
What information should be included in a reference 
laboratory report? The closest direction about content 
can be found in the ARC Good Manufacturing Prac- 
tices (GMP) Inspection Checklist which asks: "Do 
patient consultation report forms include name and 
address of Red Cross Center, patient name and identifi- 
cation numbers, date, serologic data, transfusion rec- 
ommendations or clinical significance of antibody, 
referral laboratory, and name of person sending 
report?" 
Identification 
What is the need for patient identification? There is 
no doubt that the name and address of the submitting 
and reference laboratories and the name of the patient 
must appear in the report. The submitting hospital's 
identification number for the patient should appear so 
that the report will be placed in the correct chart. As 
patients are now rapidly discharged, the reference lab- 
oratory report may not arrive at the submitting hos- 
pital until after the patient is discharged, which means 
that the correct chart will have to be found in the med- 
ical records files. 
Many patients have similar or identical first and last 
names and hospital admission codes can change with 
each admission. Therefore, social security numbers 
and birthdates would allow better identification of the 
patient by the referral reference laboratory when the 
patient is subsequently admitted, perhaps at another 
hospital, and further work is requested. 
Turnaround time 
Three dates-the date of specimen collection, the 
date of receipt by the referral laboratory, and the date 
the report is sent-should appear in the report. The 
first two dates aid in establishing the chronology of 
events if a series of specimens is sent and an evolving 
picture develops, such as the detection of new anti- 
bodies, interim transfusions, transfusion reaction 
investigations, etc. 
The third date—the date the report is sent- 
provides a means of documenting the turnaround 
time. Turnaround time can be affected by a number of 
factors, including volume and complexity of cases, 
number of reference personnel available, overtime 
availability, etc. Knowledge of turnaround time allows 
laboratory personnel to examine the system and to 
pinpoint areas that need attention. 
Many reference laboratories telephone the report to 
the submitting laboratory as soon as  the work is com- 
pleted. If blood is needed, information concerning 
availability of compatible units and crossmatching 
techniques need not await a written report. If speci- 
ficity of the antibody or antibodies has not been deter- 
mined by the end of a normal work day, the urgency of 
the patient's need for blood can be ascertained, and 
from this telephone consultation a decision can be 
made concerning the need for overtime. 
If there is no urgent need for blood and the case re- 
quires more extensive or complex testing, a prelimi- 
nary written report can be sent, indicating that a final 
report will follow later. 
What should be considered a normal turnaround 
time? This will depend on the urgency of the situation. 
Apriority policy for antibody identification or requests 
for antigen-negative blood may be based upon the fol- 
lowing prioritized list: 
1. Patients who are actively bleeding, need emer- 
gency surgery, or have hemoglobin values <= 7 
g/dL and for whom blood has been requested. 
2. Patients for whom no blood has been requested 
but- 
a. have a history of GI bleeding. 
b. are scheduled for elective surgery. 
3. Specimens for antibody identification only. 
Turnaround time for work on samples from bleeding 
patients should be as short as possible. For the second 
group, the service is usually performed in less than 24 
hours. Telephone reports should be given on both of 
these patient problems. The written report should go 
out within two to three work days. Weekends, particu- 
larly long holiday weekends, can delay the report for 
another one to two days. Specimens in the third group 
are completed within a reasonable time, which is dic- 
tated by the constraints of the first two sample groups. 
Body of the report 
The personnel at the submitting laboratory want to 
know a number of things depending upon the type of 
case: 
How did the serum and/or eluate react? 
What was done to resolve the problem? 
What antibodies were found? 
Were clinically significant antibodies excluded? 
Is there any special information about the anti- 
Can references be cited? 
Is there evidence of a transfusion reaction or 
hemolytic disease of the newborn (HDN)? 
What type of blood should be given? 
How should compatibility testing be done? 
Is there a need to contact siblings or a rare donor 
Are there contributing factors to account for 
Why does the submitting laboratory need to know 
how the patient’s specimen reacted in the reference 
laboratory? If the findings were different, there may be 
ways to explain these differences. For example, the 
submitting transfusion service laboratory’s work may 
show reactions at room temperature that became 
weaker or nonreactive in the indirect antiglobulin test. 
The referred specimen arrived and was refrigerated 
overnight before being worked on in the reference lab- 
oratory. Agglutination was not demonstrable in any 
testing phase. This information, transmitted along with 
an explanation that the referring laboratory’s results 
were probably caused by auto-anti-I and that auto- 
adsorption at 4°C can resolve that problem, could 
bodies that should be offered? 
organization for rare blood? 
serological discrepancies? 
be useful in further testing. 
Another actual situation involved a discrepant re- 
verse grouping that was not reproducible in the refer- 
ence laboratory until the sample was tested with the 
hospital’s commercially prepared reagent group A and 
B cells.* The patient had an antibody to EDTA, and the 
diluent of the reagent red cells contained EDTA to pre- 
vent lysis of the cells by hemolytic anti-A and/or antiB 
in a patient’s serum. The inhouse prepared reverse 
grouping cells, used first, did not contain EDTA. Tests 
of the patient’s serum and group O red cells suspended 
in EDTA also showed agglutination. When the hospi- 
tal’s commercial reverse grouping cells were washed, 
they gave the proper reverse grouping for this patient. 
If the investigation had not been thorough and had 
been reported as “no ABO discrepancy,” the reference 
laboratory would have lost credibility and an opportu- 
nity to study an interesting finding. 
Discrepancies between referring and reference lab- 
oratories can be due to the use of different technical 
procedures. A single elution method may not yield an 
expected antibody. For example, a recent serum 
sample containing anti-At sup(a) and anti-D required separa- 
tion by adsorption-elution. The anti-At sup(a) was adsorbed 
onto D negative At(a + ) RBC; it was recovered using a 
concentrated ether eluate but was not recovered using 
an acid elution procedure. 
In a case with a positive direct antiglobulin test 
(DAT), it may be necessary to remove IgG from the red 
cells with chloroquine or glycine-EDTA to type them. 
This should be noted on the report so the submitting 
laboratory will know that typing results were not in- 
validated by the positive DAT. In cases where the pa- 
tient has been transfused, it should be noted that red 
cell typings were performed using the patient’s 
neocytes. 
What antibodies were found? There may he dif- 
ferences between what the reference laboratory and 
what the submitting hospital find. One reason may he 
faulty interpretation. Examination of the worksheets 
from the hospital, which should accompany the 
sample, may be enlightening. Another explanation is 
that antibodies previously identified and no longer de- 
monstrable were recorded on the accompanying 
paperwork. 
Were the detected antibodies clinically significant? 
What clinically significant antibodies have been 
Is there any special information about the 
Can references be cited to support the special 
Is there evidence of a transfusion reaction? Here the 
report should be worded very carefully, especially in 
the case of an immediate reaction. Personnel should be 
prepared to testify about the legal implications of 
findings. 
excluded? 
detected antibodies that should be offered? 
information? 
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Is there evidence of HDN? Detecting an antibody in 
an infant's serum or on the red cells does not imply 
clinical HDN. The serological findings should be re- 
ported and a possible association with HDN discussed. 
What type of blood should be transfused? How 
should compatibility testing be performed? For clini- 
cally significant antibodies, there is no doubt that 
antigen-negative units are recommended. For anti- 
bodies serologically nonreactive at 30°C or below, the 
report may suggest doing crossmatches using a pre- 
warming technique. 
When clinically significant antibodies have been 
excluded in a specimen containing an HTLA antibody 
of undetermined specificity, it is acceptable to recom- 
mend that blood be selected on the basis of current se- 
rological compatibility but, when there is need for 
transfusion in the future, efforts must be made to first 
detect clinically significant antibodies. 
It is wise to let the transfusion service staff know the 
degree of difficulty in obtaining compatible units for 
future transfusion. While it may not appear critical to 
report that 91 percent of random donor units should be 
compatible with a patient's anti-K, it can be important 
to the clinician reading the report. 
When recommending antigen-negative blood for pa- 
tients with antibody to a high-incidence antigen, labo- 
ratory personnel have an opportunity to do several 
things. The patient's siblings can be recruited as a 
source of compatible units, or the patient can be en- 
couraged to store autologous units if able to do so. The 
patient's physician can be informed of the extent of dif- 
ficulty in obtaining rare blood, both for present and fu- 
ture transfusions. Is the blood available in the frozen 
inventory, or must it be recruited locally or nationally? 
Generating the report 
Some labs use a checklist of responses to be selected 
relating to the patient's case. However, a personalized 
report has more depth. Fill-in spaces for recording the 
test phases at which reactions were observed can be 
coupled with remarks about interpretations and con- 
clusions. The applicable remarks to be added can be se- 
lected from a list of comments generated for this 
purpose.* 
The final report 
The medical director, director of technical services, 
or the reference lab supervisor may review the report. 
The final written report should not depend on individ- 
uals who may not be readily available, as this will ap- 
preciably delay the mailing. 
A service offered by some reference laboratories is 
to furnish antibody identification cards (ID) to be 
carried by the patient. The card is only prepared for pa- 
tients with clinically significant antibodies. It is mailed 
along with the reference laboratory report to the hos- 
pital blood bank supervisor or transfusion service di- 
rector. Two letters should accompany the card: One of 
these letters informs the patient's physician of the clin- 
ically significant antibody found and the need to for- 
ward the ID card and other letter to the patient; the 
second letter to the patient instructs him or her to 
carry the card and present it when admitted to a hos- 
pital for surgery or pregnancy or whenever blood bank 
services are requested. 
Complete, clear, and helpful reference laboratory re- 
ports can be invaluable to the patient and to submitting 
hospital blood bank personnel. They can also gain de- 
served recognition for the reference laboratory. 
Kathryn M. Beattie, MT(ASCP)SBB, Director, Reference Laboratory 
and Technical Education, American Red Cross Blood Services, 
Southeastern Michigan Region, PO Box 33351, Detroit, MI 
48232-5351. 
A CASE REPORT PATERNITY CASE 
WITH THREE ALLEGED FATHERS 
AND A SET OF TRIPLETS 
Mary Lou Guizzo, Nancy Lang 
Introduction 
Parentage testing using combinations of genetic 
markers (red blood cell [RBC] antigens, serum pro- 
teins, RBC enzymes, and histocompatibility locus-A 
human antigens [HLA]) is capable of establishing non- 
paternity in 99 percent of the cases in which an alleged 
father is falsely accused.' If exclusion is not obtained, 
the likelihood of paternity can be determined. 
In this paternity case, three alleged fathers, a 
mother, and a set of triplets (two girls and a boy) were 
evaluated. Antigen typings of the HLA and RBC sys- 
tems and evaluation of red cell enzymes and serum 
proteins were performed. 
Materials and Methods 
Testing for red cell antigens was performed with 
commercially obtained antisera according to the man- 
ufacturer's directions. Red cell typing included testing 
with the following antisera: anti-A, -B, -AB, -A sub(1), -D, -C, 
-c, -E, -e, -C sup(w), -M, -N, -S, -s, -K, -k, -Fy sup(a), -Fy sup(b), -Jk sup(a), and -Jk sup(b). 
HLA-A and -B lymphocyte antigens were determined 
using standard lymphocytotoxicity tests sup(2) with antisera 
obtained from commercial sources. Testing was done 
in duplicate by two technologists working 
independently. 
Samples submitted for electrophoresis (serum pro- 
teins and red cell enzymes) were tested by an indepen- 
dent laboratory specializing in both conventional elec- 
trophoresis and iso-electric focusing. 
Calculations were determined using a sperm proba- 
bility test sup(3) to obtain a Paternity Index (PI) and a Rela- 
tive Chance of Paternity (RCP). The PI was defined as 
the probability that the alleged father could donate 
one sperm carrying all the obligatory genes (X), di- 
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